Overview

A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The study drug LY2409021 is being evaluated as a possible treatment for diabetes. The primary purpose of this study is to help answer the following research questions, and not to provide treatment for diabetes : - The safety of LY2409021 and any side effects that might be associated with it following 4 weeks of doses - How long it takes the body to absorb and remove LY2409021 following dosing over 4 weeks - How daily dosing of LY2409021 affects blood levels of sugar (glucose), insulin and other naturally occurring substances before and after a meal - How LY2409021 works when given with metformin - How daily dosing of LY2409021 affects the cells that produce insulin
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company